Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGB-B2033 + tislelizumab + bevacizumab
- Development stage
- Phase 2
- Lead developer
- BeOne Medicines
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BGB-B2033 + tislelizumab + bevacizumab is an investigational combination regimen being evaluated for the treatment of advanced or metastatic solid tumors, particularly glypican-3 (GPC3)-expressing malignancies such as hepatocellular carcinoma (HCC). The regimen consists of three active components: BGB-B2033, a bispecific monoclonal antibody that simultaneously targets GPC3 on tumor cells and the costimulatory receptor 4-1BB (CD137) on T cells to drive localized immune activation; tislelizumab, an anti-PD-1 monoclonal antibody designed to inhibit immune checkpoint signaling; and bevacizumab, an anti-VEGF monoclonal antibody that inhibits angiogenesis. By combining tumor-localized 4-1BB costimulation, immune checkpoint blockade, and anti-angiogenesis, this triplet therapy aims to synergistically enhance anti-tumor immune responses and overcome resistance in the tumor microenvironment. It is currently undergoing Phase 1/2 clinical development.
- Other names
- BGB-B2033 + Tevimbra + AvastinBGB-B2033 + Tevimbra + bevacizumabBGB-B2033 + tislelizumab + AvastinBGB-B2033 + tislelizumab + bevacizumabBGB-B2033, tislelizumab, and bevacizumabBGB-B2033, tislelizumab, bevacizumab
02
Targets
GPC3 (Glypican-3)PDCD1 (Programmed cell death protein 1 receptor)TNFRSF9 (CD137 extracellular domain)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on BGB-B2033 + tislelizumab + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGB-B2033 + tislelizumab + bevacizumab.